首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1352802

全球勃起功能障礙藥物市場研究報告 - 2023 年至 2030 年產業分析、規模、佔有率、成長、趨勢與預測

Global Erectile Dysfunction Drugs Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2023 to 2030

出版日期: 2023年09月01日 | 出版商:

Value Market Research | 英文 121 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

全球勃起功能障礙藥物市場需求預計將從 2022 年的 55.2 億美元增至 2030 年的近 123.8 億美元，2023-2030 年研究期間複合年成長率為 10.62%。

勃起功能障礙藥物可幫助並克服無法使勃起足夠牢固以維持性活動的問題。勃起功能障礙是一種嚴重的疾病，可能導致婚姻問題、壓力和自卑。這個問題可能是由於潛在的醫療疾病造成的，並增加了心臟病和心血管疾病的風險。市面上有一些治療方法和藥物可以幫助維持勃起。阿伐那非、西地那非、伐地那非和他達拉非是用於治療勃起功能障礙的藥物。

市場動態：

壓力大且久坐的生活方式、不斷成長的老年人口以及勃起功能障礙與心臟病和糖尿病之間的關聯是推動勃起功能障礙 (ED) 藥物市場的重要因素。由於大眾對勃起功能障礙、口服 ED 藥物的可及性和性疾病的了解不斷增加，勃起功能障礙藥物被廣泛使用。由於腎衰竭、糖尿病、高血壓、荷爾蒙失調和神經系統疾病等慢性疾病的盛行率增加，全球對勃起功能障礙藥物的需求正在上升。新興經濟體研發和藥品製造的增加將為ED藥物市場的擴張提供更好的成長可能性。

研究報告涵蓋波特五力模型、市場吸引力分析和價值鏈分析。這些工具有助於清晰地了解行業結構並評估全球範圍內的競爭吸引力。此外，這些工具也對全球勃起功能障礙藥物市場的各個細分市場進行了包容性評估。勃起功能障礙藥物產業的成長和趨勢為本研究提供了整體方法。

區域分析：

本節涵蓋區域前景，重點介紹北美、歐洲、亞太地區、拉丁美洲以及中東和非洲勃起功能障礙藥物市場當前和未來的需求。此外，該報告重點關注所有主要地區各個應用領域的需求、估計和預測。

該研究報告還涵蓋了市場主要參與者的全面概況以及對全球競爭格局的深入了解。勃起功能障礙藥物市場的主要參與者包括輝瑞公司、禮來公司、梯瓦製藥工業有限公司、賽諾菲、太陽製藥工業有限公司、拜耳公司、Petros Pharmaceuticals Inc.、VIVUS Inc.、Auxilium Pharmaceuticals Inc. 、Adamed。本節包含競爭格局的整體視圖，包括各種策略發展，例如關鍵併購、未來產能、合作夥伴關係、財務概況、合作、新產品開發、新產品發布和其他發展。

如果您有任何客製化要求，請寫信給我們。我們的研究團隊可以根據您的需求提供客製化報告。

區域展望
介紹
北美銷售分析
- 概述、歷史和預測銷售分析
- 北美按細分市場銷售分析
- 北美按國家銷售分析
- 美國銷售分析
- 加拿大銷售分析
- 墨西哥銷售分析
歐洲銷售分析
- 概述、歷史和預測銷售分析
- 歐洲按細分市場銷售分析
- 歐洲按國家銷售分析
- 英國銷售分析
- 法國銷售分析
- 德國銷售分析
- 義大利銷售分析
- 俄羅斯銷售分析
- 歐洲其他地區銷售分析
亞太地區銷售分析
- 概述、歷史和預測銷售分析
- 亞太地區按細分市場銷售分析
- 亞太地區國家/地區銷售分析
- 中國銷售分析
- 印度銷售分析
- 日本銷售分析
- 韓國銷售分析
- 澳洲銷售分析
- 亞太地區其他地區銷售分析
拉丁美洲銷售分析
- 概述、歷史和預測銷售分析
- 拉丁美洲按細分市場銷售分析
- 拉丁美洲按國家銷售分析
- 巴西銷售分析
- 阿根廷銷售分析
- 秘魯銷售分析
- 智利銷售分析
- 拉丁美洲其他地區銷售分析
中東和非洲銷售分析
- 概述、歷史和預測銷售分析
- 中東和非洲按細分市場銷售分析
- 中東和非洲國家銷售分析
- 沙烏地阿拉伯銷售分析
- 阿拉伯聯合大公國銷售分析
- 以色列銷售分析
- 南非銷售分析
- 中東其他地區和非洲銷售分析

第 8 章：勃起功能障礙藥廠的競爭格局

勃起功能障礙藥物市場競爭
夥伴關係/協作/協議
併購
新產品發布
其他發展

第 9 章：公司簡介

頂級公司市佔率分析
市場集中度
Pfizer Inc.

公司簡介
公司收入
產品
最近的發展

Eli Lilly and Company

公司簡介
公司收入
產品
最近的發展

Teva Pharmaceutical Industries Ltd

公司簡介
公司收入
產品
最近的發展

Sanofi

公司簡介
公司收入
產品
最近的發展

Sun Pharmaceutical Industries Ltd

公司簡介
公司收入
產品
最近的發展

Bayer AG

公司簡介
公司收入
產品
最近的發展

Petros Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

VIVUS Inc.

公司簡介
公司收入
產品
最近的發展

Auxilium Pharmaceuticals Inc.

公司簡介
公司收入
產品
最近的發展

Adamed

公司簡介
公司收入
產品
最近的發展

注意 - 在公司概況中，財務詳細資訊和近期發展視情況而定，或者如果是私人公司，則可能不包括在內

簡介目錄圖表

Product Code: VMR11219059

The global demand for Erectile Dysfunction Drugs Market is presumed to reach the market size of nearly USD 12.38 BN by 2030 from USD 5.52 BN in 2022 with a CAGR of 10.62% under the study period 2023 - 2030.

Erectile dysfunction drugs assist and overcome the inability to get an erection firm enough to maintain sexual activity. Erectile dysfunction is a severe illness that can lead to marital problems, stress, and low self-esteem. This issue might be due to an underlying medical ailment & increases the risk of heart & cardiovascular disease. There are treatments and drugs available on the market that can aid in maintaining an erection. Avanafil, sildenafil, vardenafil, and tadalafil are drugs used in treating erectile dysfunction.

MARKET DYNAMICS:

The adoption of a stressful & sedentary lifestyle, the growing geriatric population, and the association between erectile dysfunction & heart ailments and diabetes are among the significant factors that propel the market for erectile dysfunction (ED) drugs. Erectile dysfunction drugs are widely used because of growing public knowledge of erectile dysfunction, accessibility of oral ED drugs, and sexual illnesses. The global demand for erectile dysfunction drugs is rising due to the increased prevalence of chronic conditions such as kidney failure, diabetes, hypertension, hormonal imbalance, and neurological disorders. An increase in R&D and pharmaceutical manufacturing in emerging economies will offer better growth possibilities for the ED drugs market expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of erectile dysfunction drugs. The growth and trends of erectile dysfunction drugs industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the erectile dysfunction drugs market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

Viagra
Cialis
Zydena
Levitra
Stendra
Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Erectile Dysfunction Drugs market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the erectile dysfunction drugs market include Pfizer Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Sanofi, Sun Pharmaceutical Industries Ltd, Bayer AG, Petros Pharmaceuticals Inc., VIVUS Inc., Auxilium Pharmaceuticals Inc., Adamed. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . ERECTILE DYSFUNCTION DRUGS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Product
- 3.7.2 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . IMPACT ANALYSIS OF COVID-19 OUTBREAK

6 . GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET ANALYSIS BY PRODUCT

6.1 Overview by Product
6.2 Historical and Forecast Data
6.3 Analysis by Product
6.4 Viagra Historic and Forecast Sales by Regions
6.5 Cialis Historic and Forecast Sales by Regions
6.6 Zydena Historic and Forecast Sales by Regions
6.7 Levitra Historic and Forecast Sales by Regions
6.8 Stendra Historic and Forecast Sales by Regions
6.9 Others Historic and Forecast Sales by Regions

7 . GLOBAL ERECTILE DYSFUNCTION DRUGS MARKET ANALYSIS BY GEOGRAPHY

7.1. Regional Outlook
7.2. Introduction
7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. Rest Of Asia Pacific Sales Analysis
7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE ERECTILE DYSFUNCTION DRUGS COMPANIES

8.1. Erectile Dysfunction Drugs Market Competition
8.2. Partnership/Collaboration/Agreement
8.3. Merger And Acquisitions
8.4. New Product Launch
8.5. Other Developments

9 . COMPANY PROFILES OF ERECTILE DYSFUNCTION DRUGS INDUSTRY

9.1. Top Companies Market Share Analysis
9.2. Market Concentration Rate
9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
9.4. Eli Lilly and Company
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
9.5. Teva Pharmaceutical Industries Ltd
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
9.6. Sanofi
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
9.7. Sun Pharmaceutical Industries Ltd
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
9.8. Bayer AG
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
9.9. Petros Pharmaceuticals Inc.
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
9.10. VIVUS Inc.
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
9.11. Auxilium Pharmaceuticals Inc.
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
9.12. Adamed
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments